Anebulo Pharmaceuticals Inc (ANEB) - Kapitalisasi marang bathi resik

Anebulo Pharmaceuticals Inc - logo grafis emiten ANEB

Anebulo Pharmaceuticals (ANEB) creates unique emergency aid products, ensuring stable demand and a prolonged period of monopoly income. The business relies on a narrow niche of cannabinoid neutralization, where the primary risks are associated with a limited market. This chart of PE ratio changes reflects -1.80. The company is currently completing final trials of a first-of-its-kind antidote, focusing on a breakthrough release.

anebulo.com (ANEB): Rasio rega marang bathi saka 04.07.2022 nganti 07.03.2026

Rincian metrik komprehensif lan analitis Anebulo Pharma (ANEB)

Analisis komprehensif perusahaan:Anebulo Pharmaceuticals, Inc. ANEB
Produk mawa merek Anebulo

To assess the fundamental value of an asset, an investor compares market capitalization with annual net profit, determining the investment payback period via the P/E ratio. By analyzing the P/E ratio trend, one can identify whether Anebulo Pharmaceuticals (ANEB) is overvalued or undervalued, given that the high R&D costs associated with developing the Anebound antidote often outpace the current financial results of the biopharmaceutical sector.